Psyence Biomedical Soars as Trump Supports Psychedelic Drug Research
Psyence Biomedical's stock surged over 72% following President Trump's executive order for rapid psychedelic drug approvals and a substantial commitment to ibogaine research. The company's strong infrastructure for producing GMP-compliant ibogaine enhances their market competitiveness and aligns with increasing regulatory interest, potentially driving further investor confidence.
View signal analysis